review
summar
recent
experiment
achiev
area
develop
new
rna
interfer
rnai
therapeut
treatment
viral
respiratori
diseas
deliveri
short
interf
rna
sirna
intend
target
tissu
remain
biggest
problem
therapeut
applic
compound
appropri
formul
chemic
modif
improv
stabil
boost
probabl
util
rnai
drug
clinic
applic
viral
respiratori
infect
strike
million
peopl
year
collect
caus
death
form
infecti
diseas
common
respiratori
diseas
caus
varieti
virus
similar
trait
affect
upper
lower
respiratori
tract
common
virus
influenza
virus
respiratori
syncyti
viru
rsv
parainfluenza
virus
piv
respiratori
adenovirus
coronaviru
effect
vaccin
respiratori
virus
avail
highli
mutabl
treatment
ribavirin
amantadin
use
discoveri
rna
interfer
rnai
open
new
possibl
drug
develop
abil
rnai
silenc
express
specif
rogu
gene
provid
novel
approach
treat
wide
rang
human
disord
review
author
draw
attent
recent
develop
rnaibas
therapeut
treatment
variou
viral
respiratori
diseas
rnai
mechan
inhibit
express
specif
gene
doublestrand
rna
dsrna
rnai
long
dsrna
enzymat
cleav
dicer
dsrnaspecif
rnase
nucleotid
short
interf
rna
sirna
sirna
integr
endoribonucleasecontain
protein
complex
call
rnainduc
silenc
complex
risc
wherebi
strand
separ
antisens
strand
guid
risc
complementari
target
mrna
sequenc
key
compon
risc
call
argonaut
also
rnase
slice
target
mrna
lead
suppress
express
correspond
gene
subsequ
decreas
correspond
protein
level
thu
rnai
offer
gener
advantag
high
specif
enhanc
potenc
prophylact
therapeut
treatment
target
previous
obstin
diseasecaus
gene
effect
sirna
antivir
drug
first
evalu
tissu
cultur
result
investig
sever
research
group
demonstr
great
potenti
sirna
combat
seriou
human
anim
respiratori
virus
rsv
sever
acut
respiratori
syndrom
sar
coronaviru
influenza
adenoviru
avian
metapneumoviru
porcin
respiratori
viru
summar
rsv
nonseg
negativestrand
rna
viru
member
paramyxovirida
famili
common
caus
bronchiol
pneumonia
among
children
oneyear
old
younger
age
children
serolog
evid
rsv
infect
older
adult
individu
compromis
immun
system
heart
lung
problem
increas
risk
develop
complic
rsv
infect
rsv
caus
repeat
reinfect
throughout
life
symptom
rang
moder
sever
croup
bronchiol
pneumonia
asthma
although
develop
antirsv
vaccin
high
prioriti
none
current
avail
first
report
success
rnai
applic
antivir
agent
rsv
tissu
cultur
publish
sirna
direct
viral
fusion
f
phosphoprotein
p
shown
highli
specif
ablat
highli
effici
sirna
abl
inhibit
also
prevent
rsv
infect
anoth
respiratori
viru
segment
negativestrand
rna
genom
influenza
flu
viru
member
orthomyxovirida
famili
respons
death
annual
us
accord
cdc
us
popul
get
flu
hospit
flu
complic
everi
year
pandem
flu
recogn
sinc
earliest
record
histori
mutabl
viru
still
repres
alarm
threat
antigen
match
vaccin
circul
virus
close
vaccin
influenza
viru
prevent
infect
healthi
person
younger
year
age
compar
older
person
furthermor
viral
antigen
undergo
mutat
frequent
vaccin
influenza
need
reformul
everi
year
given
previou
year
vaccin
becom
ineffect
new
viru
subtyp
cell
cultur
embryon
chicken
egg
sirna
specif
nucleocapsid
np
compon
viral
rnadepend
rna
polymeras
rdrp
pa
abolish
accumul
correspond
mrna
also
virion
rna
complementari
rna
sirna
also
broadli
inhibit
accumul
viral
cellular
rna
two
group
research
use
differ
approach
inhibit
influenza
viru
infect
tissu
cultur
target
cellular
protein
ranbind
protein
involv
nuclear
import
assembl
viral
rdrp
essenti
viral
life
cycl
sirnamedi
knockdown
ranbind
protein
inde
result
delay
accumul
viral
rna
infect
cell
confirm
viral
also
cellular
gene
may
target
therapeut
intervent
viral
diseas
sever
acut
respiratori
syndrom
sar
coronaviru
sar
viral
respiratori
diseas
first
report
novemb
china
first
sever
new
diseas
emerg
centuri
first
outbreak
diseas
asia
result
infect
result
death
howev
case
us
report
yet
diseas
vaccin
treatment
case
respiratori
virus
sar
coronaviru
sarscov
rna
genom
viru
belong
famili
nidoviral
positivestrand
rna
virus
known
frequent
mutat
creat
difficulti
vaccin
develop
thu
need
effect
antisar
drug
overst
explor
possibl
interrupt
sarscov
replic
rnai
specif
sirna
target
viral
spike
np
rdrp
envelop
protein
gene
well
leader
sequenc
synthes
introduc
mammalian
cell
found
antisar
sirna
inhibit
viral
gene
express
result
may
suggest
new
rnaimedi
approach
treatment
prevent
sar
recent
discov
fourth
member
coronavirida
famili
infect
human
associ
acut
respiratori
ill
young
children
elderli
immunocompromis
individu
present
signific
number
respiratori
tract
ill
unknown
etiolog
viru
use
cellular
receptor
close
rel
sarscov
sirna
specif
glycoprotein
initi
entri
viru
suscept
cell
show
profound
inhibit
viral
replic
virusinfect
cell
adenoviru
famili
mediums
nonenvelop
doublestrand
dna
virus
contain
least
immunolog
distinct
type
caus
human
infect
human
adenovirus
caus
widespread
respiratori
tract
infect
although
infect
mild
requir
symptomat
treatment
case
adenoviru
serotyp
infect
immunocompromis
patient
adenoviru
infect
result
sever
complic
virusspecif
therapi
vaccin
develop
adenoviru
serotyp
avail
prevent
acut
respiratori
diseas
among
militari
recruit
cell
cultur
sirnamedi
silenc
adenovir
mrna
inhibit
viral
replic
suggest
rnaimedi
target
adenoviru
may
potenti
therapeut
effect
control
adenoviru
infect
past
sever
year
variou
studi
publish
demonstr
efficaci
silenc
diseas
gene
local
system
administr
sirna
shrna
anim
model
human
diseas
includ
respiratori
viral
infect
summar
first
evid
success
system
applic
sirna
respiratori
viral
diseas
demonstr
influenza
infect
sirna
dna
encod
shrna
direct
conserv
influenza
sequenc
deliv
lung
intraven
lowpressur
inject
abl
prevent
treat
influenza
viru
infect
given
respect
infect
find
demonstr
system
deliveri
sirna
shrna
might
use
futur
develop
antivir
therapeut
although
polyethyleneimin
pei
deliveri
reagent
use
studi
shown
undesir
toxic
studi
addit
four
differ
studi
combin
system
local
intranas
deliveri
sirna
use
combat
influenza
infect
murin
model
sirna
direct
viral
nucleoprotein
acid
polymeras
matrix
protein
abl
protect
mice
highli
pathogen
strain
influenza
viru
local
deliveri
sirna
repres
attract
mode
applic
less
invas
system
intraven
deliveri
possibl
advers
system
respons
also
minim
elimin
shown
epitheli
cell
respiratori
tract
might
transduc
vivo
sirna
signific
extent
even
without
transfect
reagent
suggest
lung
may
mean
sirna
uptak
gener
present
mammalian
cell
first
therapeut
action
sirna
lung
demonstr
sarscov
sirna
viral
spike
np
protein
high
potenc
tissu
cultur
experi
use
anim
model
infect
intranas
deliveri
sirna
virusinfect
rhesu
macaqu
sar
model
emul
sequenc
pathogenesi
human
sar
show
abrog
viral
infect
upper
airway
epitheli
cell
lead
studi
rnai
success
use
two
respiratori
virus
rsv
piv
balbc
mous
model
rsv
piv
infect
nasal
deliv
sirna
direct
essenti
viral
gene
radic
reduc
viral
titer
sirna
also
strongli
reduc
clinic
sign
infect
weight
loss
increas
respiratori
rate
patholog
featur
rsv
piv
infect
mous
dramat
improv
allerg
indic
leukotrien
level
bronchoalveolar
lavag
fluid
mice
treat
intranas
sirna
anoth
rsv
protein
nonstructur
protein
infect
rsv
show
substanti
decreas
viru
titer
lung
decreas
inflamm
airway
reactiv
compar
control
investig
persist
sirna
prophylaxi
author
treat
mice
sirna
rsv
infect
demonstr
prophylact
effect
sirna
rsv
protein
last
least
four
day
although
treatment
day
still
lower
viral
titer
tenfold
compar
control
although
research
wide
use
sirna
technolog
basic
studi
understand
gene
function
progress
develop
rnaibas
therapeut
slow
alnylam
pharmaceut
translat
success
anim
result
describ
human
trial
evalu
antivir
activ
sirna
therapeut
treatment
rsv
infect
result
rsvinfect
adult
volunt
claim
promis
compani
begun
phase
ii
studi
evalu
safeti
efficaci
experiment
infect
adult
second
quarter
result
slate
avail
earli
first
quarter
alnylam
pharmaceut
also
work
novarti
ag
rnai
drug
influenza
like
formul
similarli
anoth
preclin
rnai
player
flu
nastech
pharmaceut
announc
posit
result
nonclin
studi
sirnabas
treatment
influenza
infect
modul
gene
express
becom
new
promis
develop
therapeut
mani
seriou
diseas
take
full
advantag
approach
howev
sirna
must
appropri
effici
deliv
continu
signific
hurdl
use
novel
chitosansirna
nanoparticl
nasal
drug
deliveri
system
report
chitosan
sugarbas
polym
abl
form
selfassembl
nanoparticl
entrap
sirna
molecul
nanoparticl
taken
rapidli
cell
develop
infasurf
pulmonari
surfaceact
materi
act
select
specif
lung
allow
effici
sirna
transfect
mous
alveoli
novel
approach
need
test
anoth
challeng
vivo
applic
sirna
need
increas
stabil
sirna
chemic
modifi
chang
oligo
backbon
replac
individu
nucleotid
nucleotid
analog
other
modif
may
enhanc
mrna
target
effici
sirna
offtarget
effect
obstacl
must
overcom
minim
develop
sirna
therapi
due
fact
sirna
known
target
mrna
imperfect
complementar
may
lead
unintent
knockdown
vital
cellular
function
clearli
longterm
detail
safeti
evalu
requir
rnai
technolog
transfer
clinic
